Leslie's just reported Q2 2026 results after Tuesday's close, and the print is a study in contradictions: revenue of $184.7M beat the $162.2M estimate by 14%, but adjusted EPS came in at -$5.36 against expectations of -$4.51. The stock surged 32% in after-hours trading. Now, with another earnings event flagged for May 18, the question the market is asking is: does the revenue beat change the fundamental story, or is the earnings miss just another chapter in a prolonged decline?
Options positioning heading into the print had already turned cautious. The put/call ratio jumped to 0.89 on Tuesday — more than 2.5 standard deviations above its 20-day average of 0.52. That's the most defensive options setup seen in months, and a sharp break from the call-heavy positioning that dominated through mid-April. The shift suggests at least some options traders were braced for a stumble, not a revenue surprise.
Short positioning tells a parallel story of steady pressure. SI has climbed to 11.5% of the free float — up roughly a full percentage point from early April's 10.4% — and the ORTEX short score has been tracking at 73, in the top quartile of bearish momentum signals. Borrow remains accessible, with availability around 175% of current short interest, down from above 260% just a few weeks ago. The tightening in availability is notable: it has more than halved over the month. Cost to borrow, while easing recently, still sits near 2.8% — not expensive, but no longer falling as fast as it was. The setup is one of growing short conviction at a stock trading near $1.50, with the borrow market beginning to reflect that increased demand.
The Street is not rushing to revise its view. Mizuho cut its target to $3.50 from $4.00 last Thursday, maintaining Neutral — the fifth downward target revision from a named firm in six months. Morgan Stanley holds an Underweight with a $1.00 target, still the most bearish voice on the sell side. The consensus is a Hold, with a mean target near $2.27. That implies roughly 50% upside from Tuesday's close at $1.51 — but the target-cut trend tells a different story about analyst confidence. The EV/EBITDA multiple sits around 14.6x, which looks stretched for a company with negative earnings and a bear case built on continued traffic declines, weather headwinds, and market share erosion.
Institutional ownership adds an interesting wrinkle. Ariel Investments holds a dominant 30% of shares — a concentrated position that has not changed recently — while smaller active managers including GSA Capital and Clearfield Capital have been adding. GSA added 74,728 shares in Q1, and Clearfield entered with 160,703 shares in the prior quarter. Those are small dollar amounts at this price, but they represent genuine buy-side interest that contrasts with the short community's positioning. The insider side is quieter: recent transactions are entirely award-driven withholding sales, all at values under $800. No directional signal there.
The reaction to the last two quarterly prints gives the range of possibilities. The March 24 result (Q1 FY2026) delivered a 14% one-day gain and held that gain across the week. The February 17 print went the other way — down 11% on the day and off 16% after five sessions. With the stock up 32% after hours on the Q2 revenue beat, the more immediate focus shifts to May 18, when ORTEX flags another scheduled event — and to whether the options market's defensive lean resets now that the revenue number has cleared the bar.
See the live data behind this article on ORTEX.
Open LESL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
